Advertisement

Therapeutic Opening of the Blood-Brain Barrier in Man

  • M. K. Gumerlock
  • E. A. Neuwelt
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 103)

Abstract

The blood-brain barrier (BBB) continues to interest neuroscientists, and is studied widely in a number of animal models and disease states. The breakdown of the BBB as a consequence of disease or injury is also studied extensively in animals and humans. However, the idea of transiently opening the BBB in a controlled fashion for the purpose of achieving increased drug permeability across the barrier is a relatively new concept. To adapt these techniques to the clinical setting has been considered desirable for improved treatment of central nervous system (CNS) disease, and recent progress has made this possible.

Keywords

Single Photon Emission Computerize Tomography Malignant Glioma Primary Central Nervous System Lymphoma Malignant Brain Tumor Karnofsky Performance Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

ACNU

3-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea

BBB

Blood-brain barrier

BCNU

1,3-bis(2-chloroethyl)-1-nitrosourea

CNS

Central nervous system

CT

Computerized tomography

DTPA

Diethylenetriaminepentaacetic acid

FDA

Federal Drug Agency

ICP

Intracranial pressure

Ig

Immunoglobulin

MAb

Monoclonal antibody

MRI

Magnetic resonance imaging

PET

Positron emission tomography

PFI

Progression-free interval

SPECT

Single photon emission computerized tomography

VER

Visual evoked response

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beaumier PL, Neuzil D, Yang HM et al. (1986) Immunoreactivity assay for labeled antimelanoma monclonal antibodies. J Nucl Med 27:824–828PubMedGoogle Scholar
  2. Blasberg RG, Patlak C, Fenstermacher JD (1985) Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 195: 73–83Google Scholar
  3. Bonstelle CT, Kori SH, Rekate H (1983) Intracarotid chemotherapy of glioblastoma after induced blood-brain barrier disruption. AJNR 4:810–812PubMedGoogle Scholar
  4. Chamberlain MC, Murovic JA, Levin VA (1988) Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology 28:1371–1374Google Scholar
  5. Chiras J, Dormont D, Fauchon F, Debussche C, Bories J (1988) Intra-arterial chemotherapy of malignant gliomas. J Neuroradiol 15:31–48PubMedGoogle Scholar
  6. Ervin T, C’anellos GP (1980) Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer 45:1556–1557PubMedCrossRefGoogle Scholar
  7. Fauchon F, Chiras J, Poisson M, Rose M, Terrier L, Bories J, Guerin RA (1986) Intra-arterial chemotherapy by cisplatin and cytarabine after temporary disruption of the blood-brain barrier for the treatment of malignant gliomas in adults. J Neuroradiol 13:151–162PubMedGoogle Scholar
  8. Groothuis DR, Molnar P, Blasberg RG (1984) Regional blood flow and blood-to-tissue transport in five brain tumor models. Prog Exp Tumor Res 27:132–153PubMedGoogle Scholar
  9. Gumerlock MK, Neuwelt EA (1987) Principles of chemotherapy in brain neoplasia. In: Jellinger K (ed) Therapy of malignant brain tumors. Springer, Berlin Heidelberg New York, pp 277–348Google Scholar
  10. Gumerlock MK, Belshe BD, Madsen R, Watts C (1992) Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review. J Neurooncol 12:33–46PubMedCrossRefGoogle Scholar
  11. Heimberger K, Samec P, Podreka I, Binder H, Suess E, Reisner T, Deecke L, Steger G, Hiesmayr M, Dittrich C, Horaczek A, Zimpfer M (1987) Reversible opening of the blood-brain barrier in the chemotherapy of malignant gliomas (in German) Wien Klin Wochenschr 99:385–388PubMedGoogle Scholar
  12. Hiesmayr M, Dirnberger H, Aloy A, Heimberger K, Horaczek A, Brandstatter B, Zimpfer M (1987) Hemodynamic effects of an osmotic bolus for the reversible opening of the blood-brain barrier (in German). Schweiz Med Wochenschr 117:450–454PubMedGoogle Scholar
  13. Hildebrand J (1986) Radiotherapy and chemotherapy of malignant brain gliomas. Drugs Clin Res 12:167–175Google Scholar
  14. Houghton AN, Mintzer D, Cordon-Cardo C et al. (1985) Mouse monoclonal I3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82:1242–1246PubMedCrossRefGoogle Scholar
  15. Johnson DW, Parkinson D, Wolpert SM, Kasdon D, Kwan ES, Laucella M, Anderson ML (1987) Intracarotid chemotherapy with 1,3-Bis-(2-chloroethyl)-1- nitrosourea (BCNU) in 5% dextrose in water in the treatment of malignant glioma. Neurosurgery 20:577–583PubMedCrossRefGoogle Scholar
  16. Li V, Levin AB, Turski P (1988) Intra-arterial chemotherapy following blood-brain barrier disruption in patients with recurrent high grade astrocytomas (abstract). Proc Am Ass Neurol Surg 274:404Google Scholar
  17. Markowsky SJ, Zimmerman CL, Tholl D, Soria I, Castillo R (1991) Methotrexate disposition following disruption of the blood-brain barrier. Ther Drug Monit 13:24–31PubMedCrossRefGoogle Scholar
  18. Millay RH, Klein ML, Shults WT, Dahlborg SA, Neuwelt EA (1986) Maculopathy associated with combination chemotherapy and osmotic opening of the blood- brain barrier. Am J Ophthmol 102:626–632Google Scholar
  19. Miller DF, Bay JW, Lederman RJ, Purvis JD, Rogers LR, Tomsak RL (1985) Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas. Ophthalmology 92:402–406PubMedGoogle Scholar
  20. Miyagami M, Kagawa Y, Tusbokawa T (1985) ACNU delivery to malignant glioma tissue by osmotic blood brain barrier modification with intracarotid infusion of hyperosmolar mannitol. No Shinkei Geka 13:955–963PubMedGoogle Scholar
  21. Miyagami M, Tsubokawa T, Tazoe M, Kagawa Y (1990) Intra-arterial ACNU chemotherapy employing 20% mannitol osmotic blood-brain barrier disruption for malignant brain tumors. Neurol Med Chir (Tokyo) 30:582–590CrossRefGoogle Scholar
  22. Neuwelt EA, Dahlborg SA (1987) Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases. J Neurooncol 4:195–207PubMedCrossRefGoogle Scholar
  23. Neuwelt EA, Dahlborg SA (1989) Blood-brain barrier disruption in the treatment of brain tumors: Clinical implications. In: Neuwelt EA (ed) Implications of the blood-brain barrier and its manipulation, vol 2. Plenum, New York, pp 195–261CrossRefGoogle Scholar
  24. Neuwelt EA, Frenkel EP, Diehl JT et al (1980) Reversible osmotic blood-brain barrier disruption in humans: implications for chemotherapy of malignant brain tumors. Neurosurgery 7:44–52PubMedCrossRefGoogle Scholar
  25. Neuwelt EA, Glasberg M, Diehl J, Frenkel EP, Barnett P (1981) Osmotic blood- brain barrier disruption the posterior fossa of the dog. J Neurosurg 55:742–748PubMedCrossRefGoogle Scholar
  26. Neuwelt EA, Specht HD, Howieson J (1983) Osmotic blood-brain barrier modification: clinical documentation by enhanced CT scanning and/or radionuclide brain scanning. AJNR 4:907–913Google Scholar
  27. Neuwelt EA, Barnett PA, Frenkel EP (1984) Chemotherapeutic agent permeability to normal brain and delivery to avian sarcoma virus-induced brain tumors in the rodent: observations on problems of drug delivery. Neurosurgery 14:154–159PubMedCrossRefGoogle Scholar
  28. Neuwelt EA, Frenkel E, d’Agostino AN (1985) Growth of human lung tumor in the brain of the nude rat as a model to evaluate antitumor agent delivery across the blood-brain barrier. Cancer Res 45:2827–2833PubMedGoogle Scholar
  29. Neuwelt EA, Frenkel EP, Gumerlock MK, Braziel R, Dana B, Hill SA (1986a) Developments in the diagnosis and treatment of primary CNS lymphoma: a prospective series. Cancer 58:1609–1620PubMedCrossRefGoogle Scholar
  30. Neuwelt EA, Howieson J, Frenkel EP, Specht HD, Weigel R, Buchan CG, Hill SA (1986b) Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 19:573–582PubMedCrossRefGoogle Scholar
  31. Neuwelt EA, Specht HD, Larson S et al. (1987) Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanomaa metastatic to the central nervous system. Neurosurgery 20:885–895PubMedCrossRefGoogle Scholar
  32. Neuwelt EA, Enzmann DR, Pagel MA, Miller G (1989) Bacterial and fungal brain abscess and the blood-brain barrier. In: Neuwelt EA (ed) Implications of the blood-brain barrier and its manipulation, vol 2. Plenum, New York, pp 263–305CrossRefGoogle Scholar
  33. Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey F, Roman-Goldstein S, Braziel R, Dana B (1991) Primary central nervous system lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 9:1580–1590PubMedGoogle Scholar
  34. Phillips JP, Alderson T, Sikora K et al. (1983) Localization of malignant glioma by a radiolabeled human monoclonal antibody. J Neurosurg 46:388–392Google Scholar
  35. Roman-Goldstein SM, Barnett PA, Mormick CI, Ball MJ, Ramsey F, Neuwelt EA (1991) Imaging and toxicity of gadopentate dimeglumine administered after osmotic blood-brain barrier disruption. AJNR 12:885–890PubMedGoogle Scholar
  36. Runge VM, Price AC, Wehr CJ, Atkinson JB, Tweedle MF (1985) Contrast enhanced MRI evaluation of a canine model of osmotic blood-brain barrier disruption. Invest Radiol 20:830–844PubMedCrossRefGoogle Scholar
  37. Sato S, Toya S, Otani M (1985a) Barrier opening microcirculation in human brain tumor. No To Shinkei 37:109–113PubMedGoogle Scholar
  38. Sato S, Yoshinori A, Kodama R, Fujioka M, Otani M, Inoue H, Toya S (1985b) Blood-brain barrier opening CT. Prog Comput Tomogr 7:43–48Google Scholar
  39. Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 2:187–193PubMedGoogle Scholar
  40. Stewart DJ, Grahovak Z, Maroun J et al. (1985) Intraarterial chemotherapy for brain tumors. Proc Am Soc Clin Oncol 4:C513Google Scholar
  41. Suda K, Nakasu S, Saito A (1985) Ocular complication of combined intracarotid chemotherapy and osmotic blood-brain barrier disruption. Nippon Geka Hokan 54:359–363PubMedGoogle Scholar
  42. Williams WT, Lowry RL, Eggers GWN (1986) Anesthetic management during therapeutic disruption of the blood-brain barrier. Anesth Analg 65:188–190PubMedGoogle Scholar
  43. Yamada K, Takahama H, Nakai O, Takanashi T, Hosoya T (1989) Intra-arterial chemotherapy for malignant glioma after osmotic blood-brain barrier disruption. Gan To Kagaku Ryoho 16:2692–2696PubMedGoogle Scholar
  44. York D, Legan M, Benner S, Watts C (1984) Further studies with a noninvasive method of intracranial pressure estimation. Neurosurgery 14:456–461PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • M. K. Gumerlock
  • E. A. Neuwelt

There are no affiliations available

Personalised recommendations